Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 13.3%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 3,900 shares, a decline of 13.3% from the October 15th total of 4,500 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average trading volume of 40,100 shares, the days-to-cover ratio is presently 0.1 days.

Aileron Therapeutics Trading Down 1.9 %

Shares of NASDAQ:ALRN traded down $0.03 on Wednesday, hitting $1.55. The company’s stock had a trading volume of 909 shares, compared to its average volume of 38,384. Aileron Therapeutics has a 12 month low of $1.01 and a 12 month high of $3.40. The stock’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.59.

Aileron Therapeutics (NASDAQ:ALRN) last posted its quarterly earnings data on Friday, October 13th. The company reported ($0.40) EPS for the quarter. Equities analysts predict that Aileron Therapeutics will post -1.4 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in ALRN. Geode Capital Management LLC grew its position in Aileron Therapeutics by 23.2% during the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock worth $68,000 after purchasing an additional 10,311 shares in the last quarter. Renaissance Technologies LLC raised its position in Aileron Therapeutics by 65.5% during the third quarter. Renaissance Technologies LLC now owns 190,691 shares of the company’s stock valued at $39,000 after buying an additional 75,500 shares during the period. Finally, Envestnet Asset Management Inc. boosted its position in Aileron Therapeutics by 52.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock worth $38,000 after acquiring an additional 63,651 shares during the period. Institutional investors and hedge funds own 22.53% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.